AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KSEP 182 min read$INM

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Stockholders’ Equity Compliance

InMed Pharmaceuticals Inc. (INM) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Nasdaq: INM c/o Norton Rose Fulbright Canada LLP Suite 1800-510 West Georgia St. Vancouver, BC, Canada V6B 0M3 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Stockholders’ Equi

Original reporting
SEC EDGAR 8-K
Published Sep 18, 2026, 9:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 9:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$INM
Bearish
medium confidence
Mentioned
$INM
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$INMBearishMed
01

Why it matters

The notice creates short‑term downside risk, but the announced $490M merger financing could restore compliance and support the share price if completed.

02

Market read

Compliance notice is a material corporate event for a micro‑cap biotech, affecting its liquidity and valuation.

03

What to watch

Potential for a Nasdaq extension and appeal process may give the company more time than the market assumes.

Relevance 7/10Novelty 7/10Timing: immediate

Background

InMed Pharmaceuticals filed an 8‑K reporting a Nasdaq compliance notice due to shareholders' equity below the required threshold, linked to merger‑related expenses and other costs.

Company-level read

Ticker impact

$INMBearishMedium confidence
Context

Nasdaq notified InMed Pharmaceuticals that its shareholders' equity fell below the $2.5M minimum, threatening delisting unless compliance is regained.

Expected impact

Downside pressure in the short term, with upside if merger proceeds and equity recovers.

Evidence & confidence

Equity shortfall is material for a Nasdaq-listed micro‑cap; market reacts to compliance threats, but merger financing offers a path to recovery.

Market effects

Sector

Highlights compliance risk for other small‑cap biotech firms on Nasdaq Capital Market.

Regional

Limited to US-listed biotech sector; no broader regional effect.

Global

Minimal global impact; primarily a company‑specific regulatory issue.

Counterpoint

What could challenge this read

If the merger closes as planned, the equity boost could quickly resolve the issue, making the stock a potential rebound play.

Key entities

  • company
    InMed Pharmaceuticals Inc.

    Nasdaq‑listed biotech facing equity compliance issue.

  • company
    Mentari Therapeutics, Inc.

    Merger partner providing pre‑closing financing.

Read at source← All news

Related articles

OCT 27
$INMMed

InMed Pharmaceuticals: InMed Announces CVR Distribution Record Date in Connection with Proposed Merger

InMed Pharmaceuticals (NASDAQ: INM) set November 5, 2026, as the record date for distributing contingent value rights (CVRs) to shareholders, pending approval of the merger with Mentari Therapeutics and shareholder approval of the Return of Capital Proposal at the November 4, 2026, meeting. The CVRs will be issued under a CVR Agreement, with each shareholder receiving one CVR per common share held as of the record date, but no CVRs will be issued for shares from stock options.

finanznachrichten.de1 min
SEP 9
$INMMed

InMed Pharmaceuticals: InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update

InMed Pharmaceuticals (INM) reported a net loss of $12.9M for FY2026, up from $8.2M in FY2025. The company is pursuing a merger with Mentari Therapeutics, expected to close by year-end, with Mentari raising $490M in pre-closing financing. InMed's legacy programs, including INM-901, INM-089, and INM-755, are being pursued for strategic opportunities. The company had $2.2M in cash as of June 30, 2026.

finanznachrichten.de2 min
JUL 22
$INMMed

InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline - InMed Pharmaceutica

Mentari Therapeutics raised an additional $200 million via a private placement ahead of its planned merger with InMed Pharmaceuticals (NASDAQ:INM). The deal also closes alongside a previously announced $290 million private placement. Funds extend Mentari’s cash runway into 2029 to support Phase 2a readouts for PACAP-targeted programs, including MT-002. Post-merger, the company will trade on Nasdaq under a new ticker.

benzinga.com4 min
JUL 6
$INMMed

InMed Pharmaceuticals: InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4

InMed Pharmaceuticals (NASDAQ: INM) said it amended a previously announced all-stock merger agreement with privately held Mentari Therapeutics and its merger subsidiaries. InMed filed a preliminary Form S-4 with the SEC for the deal. The boards approved; closing is expected in Q4 2026, pending shareholder approvals and S-4 effectiveness.

finanznachrichten.de3 min
JUN 4
$INMMedAI 8/10

InMed Pharmaceuticals: InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements

InMed Pharmaceuticals (NASDAQ: INM) said Nasdaq notified it on June 3, 2026 that it has regained compliance with Nasdaq Listing Rule 5550(a)(2) after its closing bid stayed at or above $1.00 for 10 straight business days (May 19–June 2). Nasdaq had flagged a failure to meet the $1.00 minimum for 30 days ending March 27. Nasdaq said the matter is closed.

finanznachrichten.de4 min